Helpful Hints
- Ask for clarification of information if necessary
-Take notes of the numbers
-Take time to plan out how to approach the calculation ‘
-Describe your approach and talk the interviewer through your calculation
QUESTION 4: Post-acquisition, Ola'Pharma believes that it will be necessary
to consolidate all biologicals R&D into one center. There are two logical
choices: 0Ia'Pharma‘s existing headquarters in Germany, and Biofuture's current
headquarters in San Francisco. OldPharma does not have any current
biologicals facilities or operations in Germany, so new facilities would have to
be built. How would you think about this decision?
QUESTION 5: While researching the integration barriers, the team learns that
one of Ola’Pharma’s top competitors, DrugMax, has already partnered with
BioFuture on their drug candidate essentially agreeing to split all development
costs and future profits 50/50. oldPharma is considering buying out DrugMax’s
50% share of the BioFuture lead drug candidate. As a first step in valuation,
they have asked the McKinsey team to estimate the potential peak sales of this
drug candidate — this is another way to verify potential future profits of a drug.
The drug candidate is intended to treat non—I-Hodgkin’s lymphoma. New cases
are diagnosed each year in 25 out of every 100,000 U .S. men and 15 out of
Helpful Hints
- Ask for clarification of information if necessary
-Take notes of the numbers
-Take time to plan out how to approach the calculation ‘
-Describe your approach and talk the interviewer through your calculation
QUESTION 4: Post-acquisition, Ola'Pharma believes that it will be necessary
to consolidate all biologicals R&D into one center. There are two logical
choices: 0Ia'Pharma‘s existing headquarters in Germany, and Biofuture's current
headquarters in San Francisco. OldPharma does not have any current
biologicals facilities or operations in Germany, so new facilities would have to
be built. How would you think about this decision?
QUESTION 5: While researching the integration barriers, the team learns that
one of Ola’Pharma’s top competitors, DrugMax, has already partnered with
BioFuture on their drug candidate essentially agreeing to split all development
costs and future profits 50/50. oldPharma is considering buying out DrugMax’s
50% share of the BioFuture lead drug candidate. As a first step in valuation,
they have asked the McKinsey team to estimate the potential peak sales of this
drug candidate — this is another way to verify potential future profits of a drug.
The drug candidate is intended to treat non—I-Hodgkin’s lymphoma. New cases
are diagnosed each year in 25 out of every 100,000 U .S. men and 15 out of
การแปล กรุณารอสักครู่..